Comparative Pharmacology
Head-to-head clinical analysis: DISOBROM versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOBROM versus PROMETHAZINE DM.
DISOBROM vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DISOBROM is a synthetic compound that acts as a partial agonist at benzodiazepine sites on GABAA receptors, potentiating GABAergic neurotransmission. It also exhibits antagonistic activity at peripheral benzodiazepine receptors (TSPO).
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
DISOBROM is not a recognized drug. Please verify the name.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (20-30%); fecal excretion accounts for <10%.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine / Antiemetic